GOSS News and Press, Gossamer Bio Inc. From 11/10/20

Gossamer Bio (GOSS): Q3 GAAP EPS of -$0.80 beats by $0.04.Cash, equivalents and marketable securities totaled $555M.Shares -0.65%.Press Release For further details see: Gossamer Bio EPS beats by $0.04

- GB004: SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC) - - GB002: TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH) - - GB1275: Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial i...

Enrollment completed in the 28-day Phase 2 razuprotafib glaucoma trial; topline data expected to be reported in December 2020 or possibly in early January 2021 Initiated second clinical trial to evaluate razuprotafib for the prevention and treatment o...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2020 financia...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB1275 at...

Insider buying decreased once again last week. Notable Insider Buys: Gossamer Bio, Inc., Selecta Biosciences, Inc., Citigroup Inc., Loop Industries, Inc., and BioVie Inc. Notable Insider Sells: Okta, Inc., Paycom Software, Inc., Apple Inc., salesforce.com, inc., and Workday, Inc. ...

Cerus Corporation inks FDA contract for Pathogen Reduction technology. Twist Biosciences strikes new deal for T Cell therapies. Gossamer Bio announces disappointing data for Asthma and Chronic Rhinosinusitis trials. For further details see: Cerus Inks FDA Contract, And O...

Gainers: Medigus (MDGS) +74%.PEDEVCO (PED) +46%.Larimar Therapeutics (LRMR) +23%.Oblong (OBLG) +23%.Blonder Tongue Laboratories (BDR) +21%.BiondVax Pharmaceuticals (BVXV) +19%.Enlivex Therapeutics (ENLV) +19%.Aileron Therapeutics (ALRN) +17%.MoneyGram International (MGI) +15%.ReneSo...

Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent ...

Gossamer Bio (GOSS) -32% after two studies in GB001, Phase 2B LEDA trial in eosinophilic asthma and Phase 2 TITAN trial in chronic rhinosinusitis, failed to meet the primary endpoints.Wah Fu Education (WAFU) -23%.Hexindai (HX) -20%.Medley Management (MDLY) -19%.I...